한빛사논문
- 조회454
Moonkyoung Jeong1, Yuna Jung2, Junyong Yoon1, Jinyoung Kang3, SeoHyeon Lee2, Woojin Back1, Hyoyeon Kim1, Michael J. Sailor3,4, Dokyoung Kim2,*, and Ji-Ho Park1,*
1Department of Bio and Brain Engineering and KAIST Institute for Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea
2Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
3Department of Nanoengineering and 4Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093, USA
*Email for D.K, J.-H.P.
Corresponding Authors: Dokyoung Kim, Ji-Ho Park
Abstract
The lack of drugs that target both disease progression and tissue preservation makes it difficult to effectively manage rheumatoid arthritis (RA). Here, we report a porous silicon-based nanomedicine that efficiently delivers an antirheumatic drug to inflamed synovium while degrading into bone-remodeling products. Methotrexate (MTX) is loaded into the porous silicon nanoparticles using a calcium silicate based condenser chemistry. The calcium silicate–porous silicon nanoparticle constructs (pCaSiNPs) degrade and release the drug preferentially in an inflammatory environment. The biodegradation products of the pCaSiNP drug carrier are orthosilicic acid and calcium ions, which exhibit immunomodulatory and antiresorptive effects. In a mouse model of collagen-induced arthritis, systemically administered MTX-loaded pCaSiNPs accumulate in the inflamed joints and ameliorate the progression of RA at both early and established stages of the disease. The disease state readouts show that the combination is more effective than the monotherapies.
논문정보
- Research article
- 2022년 10월 (BRIC 등록일 2022-10-27)
- 국내(교신)+국외 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기
